BrightSpring Health Services (BTSG) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue reached $2.91 billion, up 28.8% year-over-year, with Adjusted EBITDA of $151 million, up 15.7% year-over-year, driven by strong growth in Pharmacy Solutions and Provider Services.

• Net loss narrowed to $9.0 million from $130.1 million in Q3 2023, reflecting improved operating results and lower legal settlement costs.

• Raised 2024 revenue and Adjusted EBITDA guidance, reflecting continued operational execution, market expansion, and confidence in future growth.

• Completed IPO in January 2024, settled major litigation, and expanded through acquisitions, including Haven Hospice.

• Loss per share improved to $0.04 from $0.18, and Adjusted EPS increased to $0.11 from $(0.08).

Financial highlights

• Pharmacy Solutions revenue was $2,265.7 million, up 35.4% year-over-year; Provider Services revenue was $641.1 million, up 9.9% year-over-year.

• Gross profit for Q3 2024 was $408 million, up 13.9% year-over-year, with gross margin at 14.0%, down from 15.9% in Q3 2023.

• Adjusted EBITDA margin for Q3 2024 was 5.2%, with Pharmacy Solutions at 4.4% and Provider Services at 14.5%, up 50 basis points year-over-year.

• Adjusted EPS for Q3 2024 was $0.11.

• Cash and cash equivalents increased to $35.97 million as of September 30, 2024.

Outlook and guidance

• 2024 revenue guidance raised to $11,000–$11,300 million; Pharmacy Solutions $8,500–$8,750 million, Provider Services $2,500–$2,550 million.

• Adjusted EBITDA guidance increased to $580–$585 million, representing 14.2%–15.2% growth year-over-year, excluding certain 2023 items.

• Expect margin expansion in Q4, driven by generic launches, new hospice rates, and operational efficiencies.

• Long-term leverage target of 3x within 2–3 years; current leverage ratio at 4.39x.

• Ongoing investments in technology, automation, and de novo locations to support future growth.